Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
EDQM
0
USP
0
JP
0
Others
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
Weekly News Recap #Phispers
LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
About the Company : LGM Pharma is a global leader in sourcing hard-to-find APIs and intermediates for the pharmaceutical and biotech industries. LGM is also a full service CDMO providing formulation, ...
Shanghai Minbiotech is the leading producer of biopharmaceuticals and a variety of high-end generic & innovative drugs.
About the Company : Headquartered in Fengxian District, Shanghai Minbiotech Co., Ltd. is a company specializing in the R&D and production of advanced pharmaceutical intermediates and biological API...
About the Company : Beijing Mesochem Technology Co. Ltd., which is located in the national economic and technological development area of Yizhuang, China, manufactures pharmaceutical chemicals, fine c...
About the Company : Conscientia Industrial is a pharmaceutical company, mainly developing, manufacturing, marketing APIs (Active Pharmaceutical Ingredients), intermediates, fine chemicals in China. We...
About the Company : Hebei Huarong Pharmaceutical Co., Ltd (HRPC) is jointly invested by CSPC and Taoyuan Group, CSPC send people for administration. The company was established in 1993, which is mainl...
About the Company : Established in 1997, Nanogen Pharmaceutical Biotechnology JSC has been striving to become a world-class innovative biotechnology company in the pharmaceutical industry. We are pro...
RLD :
TE Code :
Brand Name : OMLYCLO
Dosage Form : INJECTABLE;INJECTION
Dosage Strength : 75MG/0.5ML
Approval Date :
Application Number : 761399
RX/OTC/DISCN :
RLD :
TE Code :
RLD :
TE Code :
Brand Name : OMLYCLO
Dosage Form : INJECTABLE;INJECTION
Dosage Strength : 150MG/ML
Approval Date :
Application Number : 761399
RX/OTC/DISCN :
RLD :
TE Code :
RLD :
TE Code :
Brand Name : XOLAIR
Dosage Form : VIAL
Dosage Strength : 150MG/VIAL
Approval Date :
Application Number : 103976
RX/OTC/DISCN :
RLD :
TE Code :
RLD :
TE Code :
Brand Name : XOLAIR
Dosage Form : SYRINGE
Dosage Strength : 75MG/0.5ML
Approval Date :
Application Number : 103976
RX/OTC/DISCN :
RLD :
TE Code :
RLD :
TE Code :
Brand Name : XOLAIR
Dosage Form : SYRINGE
Dosage Strength : 150MG/ML
Approval Date :
Application Number : 103976
RX/OTC/DISCN :
RLD :
TE Code :
RLD :
TE Code :
Brand Name : XOLAIR
Dosage Form : SYRINGE
Dosage Strength : 300MG/2ML
Approval Date :
Application Number : 103976
RX/OTC/DISCN :
RLD :
TE Code :
Global Sales Information
Company : Genentech, Inc.
Omalizumab
Drug Cost (USD) : 254,056,609
Year : 2023
Prescribers : 9161
Prescriptions : 79113
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company : Genentech, Inc.
Omalizumab
Drug Cost (USD) : 208,230,097
Year : 2022
Prescribers : 8052
Prescriptions : 68699
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company : Genentech, Inc.
Omalizumab
Drug Cost (USD) : 161,212,650
Year : 2021
Prescribers : 6736
Prescriptions : 54013
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company : Genentech, Inc.
Omalizumab
Drug Cost (USD) : 150,601,321
Year : 2020
Prescribers : 6456
Prescriptions : 49179
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company : Genentech, Inc.
Omalizumab
Drug Cost (USD) : 147,919,046
Year : 2019
Prescribers : 6515
Prescriptions : 45771
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company : Genentech, Inc.
Omalizumab
Drug Cost (USD) : 138,941,935
Year : 2018
Prescribers : 6137
Prescriptions : 40026
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company : Genentech, Inc.
Omalizumab
Drug Cost (USD) : 120,407,241
Year : 2017
Prescribers : 5423
Prescriptions : 34919
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company : Genentech, Inc.
Omalizumab
Drug Cost (USD) : 79,002,423
Year : 2016
Prescribers : 3844
Prescriptions : 23913
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Main Therapeutic Indication : Immunology
Currency : USD
2019 Revenue in Millions : 2,028
2018 Revenue in Millions : 1,969
Growth (%) : 3
Main Therapeutic Indication : Immunology
Currency : USD
2020 Revenue in Millions : 2,121
2019 Revenue in Millions : 2,194
Growth (%) : -3
Main Therapeutic Indication : Respiratory Disorders
Currency : USD
2020 Revenue in Millions : 1,251
2019 Revenue in Millions : 1,173
Growth (%) : 7
Main Therapeutic Indication : Immunology
Currency : USD
2021 Revenue in Millions : 2,090
2020 Revenue in Millions : 2,018
Growth (%) : 2
Main Therapeutic Indication : Respiratory Disorders
Currency : USD
2021 Revenue in Millions : 1,428
2020 Revenue in Millions : 1,251
Growth (%) : 14
Main Therapeutic Indication : Immunology
Currency : USD
2022 Revenue in Millions : 1,365
2021 Revenue in Millions : 1,428
Growth (%) : -4
Main Therapeutic Indication : Immunology
Currency : USD
2022 Revenue in Millions : 2,414
2021 Revenue in Millions : 2,090
Growth (%) : 15
Main Therapeutic Indication : Immunology
Currency : USD
2023 Revenue in Millions : 2,525
2022 Revenue in Millions : 2,414
Growth (%) : -1
Main Therapeutic Indication : Immunology
Currency : USD
2023 Revenue in Millions : 1,463
2022 Revenue in Millions : 1,365
Growth (%) : 7
Main Therapeutic Indication : Immunology
Currency : USD
2024 Revenue in Millions : 1,643
2023 Revenue in Millions : 1,463
Growth (%) : 12
Market Place
Reply
25 Apr 2024
Reply
18 Mar 2023
Patents & EXCLUSIVITIES
ABOUT THIS PAGE